Vaxcyte, Inc. — Director's Dealing 2024

Dec 10, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-12-06

Reporting Person: Paya Carlos V (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-12-06	Common Stock	G	2500	—	Disposed	1550	Direct
2024-12-06	Common Stock	A	2500	—	Acquired	5625	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-09	Stock Option (right to buy)	$72.51	G	7250	Disposed	2034-06-05	Common Stock (7250)	Direct
2024-12-09	Stock Option (right to buy)	$72.51	A	7250	Acquired	2034-06-05	Common Stock (7250)	Indirect

Footnotes

F1: The reported transactions involve the Reporting Person's transfer of certain securities to a trust for the sole benefit of the Reporting Person.

F2: As previously disclosed in Reporting Person's Form 4 filed on June 10, 2024, this represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

F3: Shares are held directly by a trust for the sole benefit of the Reporting Person.

F4: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.